Dermatology
| Vitiligo
Dermatology
Vitiligo

Update on JAK Inhibition for Vitiligo

book_2 Source: AAD VMX 2020 - Oral session
calendar_today Published on Medfyle: June 2020
import_contacts 7 min
headphones 4 min

In this medfyle

Expert commentary by Aunna Pourang, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Acknowledgements
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the AAD Virtual Meeting Experience and presented by:

David Rosmarin, MD
Tufts Medical Center, Boston, MA, USA

The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Hassan Galadari, MD, FAAD, the scientific editor of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Aunna Pourang, MD
Henry Ford Hospital
Department of Dermatology
Detroit, MI

About the Expert
Read more arrow_downward Hide arrow_upward

Aunna Pourang, MD
Henry Ford Hospital
Department of Dermatology
Detroit, MI

Aunna Pourang MD is a clinical research fellow in the Department of Dermatology at Henry Ford Hospital. She has been a subinvestigator for clinical trials involving the skin microbiome, vitiligo, atopic dermatitis, psoriasis, alopecia areata and JAK inhibitors. She has coauthored several manuscripts and book chapters and has been an assistant editor for the Dermatology Online Journal. In addition to presenting at various conferences, she was selected as candidate for the 2020 Winter Clinical Conference Rising Derm Stars® competition. Her research interests in dermatology include how the gut and skin microbiome affect skin diseases, complex medical dermatology, photomedicine and preventive health.

References
Read more arrow_downward Hide arrow_upward

1. Bickers DR, Lim HW, Marglois D, et al. The Burden of Skin Diseases: 2004 a Joint Project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55(3):490–500.

2. Elbuluk N, Ezzedine K. Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients. Dermatol Clin 2017;35(2):117–28.

3. Van den Boorn JG, Konijnenberg D, Dellemijn TAM, et al. Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells From Vitiligo Patients. J Invest Dermatol 2009;129(9):2220–32.

4. Harris JE, Harris TH, Weninger W, et al. A Mouse Model of Vitiligo With Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8⁺ T-cell Accumulation in the Skin. J Invest Dermatol 2012;132(7):1869–76.

5. Rashighi M, Harris JE. Interfering With the IFN-γ/CXCL10 Pathway to Develop New Targeted Treatments for Vitiligo. Ann Transl Med 2015;3(21):343.

6. Rothstein B, Joshipura D, Saraiya A, et al. Treatment of Vitiligo With the Topical Janus Kinase Inhibitor Ruxolitinib. J Am Acad Dermatol 2017;76(6):1054–60.

7. Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of Vitiligo With the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-week Open-Label Extension Study With Optional Narrow-Band Ultraviolet B. J Am Acad Dermatol 2018;78(6):1205–07.

8. Regazzetti C, Joly F, Marty C, et al. Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. J Invest Dermatol 2015;135(12):3105–14.

9. Harel S, Higgins CA, Cerise JE, et al. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth. Sci Adv 2015;1:e:1500973.


Feedback